- Home
- RYTM vs TMHC Comparison
RYTM vs TMHC Comparison
Compare RYTM & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | TMHC |
|---|---|---|
| Founded | 2008 | 1936 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.2B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RYTM | TMHC |
|---|---|---|
| Price | $112.03 | $62.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $125.77 | $76.83 |
| AVG Volume (30 Days) | ★ 887.7K | 846.6K |
| Earning Date | 11-04-2025 | 10-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.21 |
| EPS | N/A | ★ 8.31 |
| Revenue | $174,334,000.00 | ★ $8,378,329,000.00 |
| Revenue This Year | $47.34 | N/A |
| Revenue Next Year | $57.18 | N/A |
| P/E Ratio | ★ N/A | $7.53 |
| Revenue Growth | ★ 54.92 | 6.98 |
| 52 Week Low | $45.91 | $51.90 |
| 52 Week High | $122.20 | $72.50 |
Technical Indicators
Market Signals| Indicator | RYTM | TMHC |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 52.06 |
| Support Level | $109.59 | $60.06 |
| Resistance Level | $122.20 | $63.42 |
| Average True Range (ATR) | 5.23 | 1.60 |
| MACD | 1.04 | 0.06 |
| Stochastic Oscillator | 54.25 | 45.63 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.